Clinical application of opioid equianalgesic data

被引:173
作者
Gammaitoni, AR
Fine, P
Alvarez, N
McPherson, ML
Bergmark, S
机构
[1] Endo Pharmaceut Inc, Chadds Ford, PA 19317 USA
[2] Univ Utah, Pain Management Ctr, Salt Lake City, UT USA
[3] Univ Maryland, Sch Pharm, Baltimore, MD 21201 USA
[4] Univ Sci Philadelphia, Aldan, PA USA
关键词
opioid; dosing; equianalgesia; opioid dose conversion; equianalgesic ratios;
D O I
10.1097/00002508-200309000-00002
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Physicians and other healthcare professionals may often be faced with the need to change opioids during the course of a patient's opioid analgesic care due to a number of clinical reasons. The act of converting opioid analgesics, for many physicians, nurses, and pharmacists, who do not receive adequate training, remains a challenging and often uncomfortable aspect of pain treatment. Part of the challenge clinicians face is secondary to the relatively weak literature evidence base that exists to support the equianalgesic ratios provided in textbooks, journals, and other medical resources. Another aspect involves the lack of a widely recognized treatment algorithm or guideline to assist clinicians with opioid conversion. The final decision on which opioid dose to prescribe must involve a thorough clinical assessment to minimize the risk of prescribing inappropriate opioid doses over or under the patient's actual need. The purpose of this paper is to provide the clinician with an approach for dealing with the conversion between opioid analgesics that is standardized, yet allows for individualized results to meet unique patient needs. We present a 5-step process as a guide for clinicians faced with the need to change a patient's opioid regimen. This approach may help to build a comfort level when dealing with the clinical challenges of converting from one opioid to another.
引用
收藏
页码:286 / 297
页数:12
相关论文
共 28 条
[1]   Accuracy in equianalgesic dosing: Conversion dilemmas [J].
Anderson, R ;
Saiers, JH ;
Abram, S ;
Schlicht, C .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2001, 21 (05) :397-406
[2]  
[Anonymous], 1994, AHCPR PUBLICATION
[3]  
[Anonymous], 2001, Goodman Gilman's
[4]  
BEAVER WT, 1978, J PHARMACOL EXP THER, V207, P92
[5]  
BEAVER WT, 1978, J PHARMACOL EXP THER, V207, P101
[6]   Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model [J].
Curtis, GB ;
Johnson, GH ;
Clark, P ;
Taylor, R ;
Brown, J ;
O'Callaghan, R ;
Shi, M ;
Lacouture, PG .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (06) :425-429
[7]   Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain [J].
Donner, B ;
Zenz, M ;
Tryba, M ;
Strumpf, M .
PAIN, 1996, 64 (03) :527-534
[8]   Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA [J].
Dunbar, PJ ;
Chapman, CR ;
Buckley, FP ;
Gavrin, JR .
PAIN, 1996, 68 (2-3) :265-270
[9]  
Fitzgibbon D.R., 2001, BONICAS MANAGEMENT P, P659
[10]   Methadone in cancer pain management: Individualize dose and titrate to effect [J].
Foley, KM ;
Houde, RW .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3213-3215